Kyowa Kirin (France)

Kyowa Kirin (France)

Kyowa Kirin Co., Ltd. is a Japanese pharmaceutical and biotechnology company under the Kirin Holdings, and is among the 40 largest in the world by revenue. The company is headquartered in Chiyoda-ku, Tokyo and is a member of the Nikkei 225 stock index. Derived from Wikipedia licensed CC-BY-SA.

Open Access statistics for Kyowa Kirin (France), France, covering academic research published from 2003 to 2023. Read More.


Open Access Percentage

77%


Total
Publications

86


Total Open
Publications

66


Total
Citations

313


Open Access
Percentage

77%


Total
Publications

86


Total Open
Publications

66


Total
Citations

313

Wikipedia

Website

download

Breakdown

42% 26% 9% 23%

Publisher Open

42%

Both

26%

Other Platform Open

9%

Closed

23%

Percentage of Open Access over time

0%10%20%30%40%50%60%70%80%90%100%
200320042005200620072008200920102011201220132014201520162017201820192020202120222023

Publisher Open

Both

Other Platform Open

Closed

Volume of Open Access over time

01234567891011121314Total Publications
200320042005200620072008200920102011201220132014201520162017201820192020202120222023

Open

Closed

Publisher Open

9%OA Journal

OA Journal 9%

5

Hybrid 26%

15

No Guarantees 65%

38

Other Platform Open

Domain 40%

12

Institution 30%

9

Preprint 20%

6

Other Internet 17%

5

Public 7%

2

Other Platform Locations

Name

Platform Type

Publications

PubMed Central
Domain
11
Research Square
Preprint
8
Istanbul University - DergiPark
Institution
4
Europe PMC
Domain
4
Le Centre pour la Communication Scientifique Directe - HAL - Université de Nantes
Institution
3
Semantic Scholar
Public
2
Le Centre pour la Communication Scientifique Directe - HAL - memSIC
Other Internet
2
Le Centre pour la Communication Scientifique Directe - HAL - IN2P3
Other Internet
2
Universidade de Coimbra - Industrias Culturais
Other Internet
1
Le Centre pour la Communication Scientifique Directe - HAL - UFC - Université de Franche-Comté
Institution
1
1 / 2

Data updated 8 December 2024

Share

Share

Share